Creating Value Through Breakthrough Science

NorthSea Therapeutics B.V. (NST), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, has announced that the results of the ICONA phase 2b study for the treatment of NASH, will be presented as an oral late-breaker at the AASLD Liver

Zeotap Data, a leading provider of fully-consented, people-based data solutions, is proud to introduce Validated Demos the key to delivering reach and frequency metrics against your core demographic audience in programmatic media buying. Through exclusive partnerships with Europe’s major mobile telco operators, Zeotap Data employs cutting-edge modelling techniques to leverage

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced results from the Phase 2 trial of VTX958 in patients with moderate to severe plaque psoriasis and provided a

NorthSea Therapeutics B.V. (NST), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, has announced that one of its novel Structural Engineered Fatty Acids (SEFAs), SEFA-6179, has been granted Rare Pediatric Disease (RPD) Designation by the United States Food and

Glydways, a leader in developing on-demand Personal Rapid Transit (PRT), has announced its $56 million Series B round, including the conversion of notes valued at more than $28 million and led by New Science Ventures with participation from The ACS Group and Gates Frontier. Khosla Ventures, Glydways first investor, is

Paragraf, the first company in the world to mass produce graphene-based electronic devices using standard semiconductors processes, was named Business of the Year in the 33rd annual Business Weekly Awards on 14 September 2023. Co-founders Simon Thomas – the CEO – and CSO Professor Sir Colin Humphreys received the coveted

Zeotap CDP, the easy, secure and impactful Customer Data Platform (CDP) has established a strategic partnership with Artefact, a global data consulting service specialist. This collaboration will help to deliver effective data-driven marketing while prioritising consumer privacy and security. Enterprises will benefit from a holistic and integrated approach that will

VUV Analytics, Inc. is proud to announce the publication of ASTM D8519-23, a groundbreaking new method for the Determination of Hydrocarbon Types in Waste Plastic Process Oil using Gas Chromatography with Vacuum Ultraviolet Absorption Spectroscopy (GC-VUV). This method is the first of its kind, designed to accurately characterize WPPO produced

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that the first subject has been dosed in a Phase 1 trial of VTX3232, a novel central nervous system

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, has announced that the Company has completed patient enrollment in the Phase 2 trial of VTX002 in ulcerative colitis and the

Novadip Biosciences SA (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, has announced that the first patient has been implanted with its investigational tissue regeneration product, NVD-003, in its

Trellis Bioscience Inc, a clinical stage privately held biotechnology company focused on the discovery and development of native human monoclonal antibodies, has announced a clinical proof-of-concept milestone from a planned interim analysis of the company's Phase 1 trial of its lead antibody, TRL1068 (calpurbatug), in patients with prosthetic joint infections

Paragraf, the only company in the world to mass produce graphene electronics using transfer-free graphene and standard semiconductor processes, has acquired Cardea Bio, the world’s leading producer of graphene-based biocompatible chips. Cardea Bio is to be renamed Paragraf USA and the San Diego facility, team and operations have already become

VUV Analytics, Inc. has announced that it has raised $20 million in equity financing—led by existing investors S3 Ventures and New Science Ventures—bringing its total funding to over $36 million.  The announcement follows the recent launch of the company’s LUMA product and a record year for revenue with its unit

ProterixBio, Inc. has announced the offering of the Presage® ST2 Assay as a testing service through ProterixBio’s high-complexity CLIA laboratory. This Assay has been FDA cleared for use in conjunction with clinical evaluation as an aid in assessing the prognosis of patients diagnosed with chronic heart failure. Heart failure is

Picocom, the 5G Open RAN baseband semiconductor and software specialist, has announced Antevia Networks has selected Picocom’s award-winning silicon technology to empower its new innovative 5G in-building solutions. The partnership combines Antevia Networks’ technology with Picocom’s latest generation 5G system-on-chip silicon to drive innovations to address the many challenges of

Isorg, a pioneer in Organic PhotoDetectors (OPDs) and large area image sensors, announces further details on the company’s collaboration with Precise Biometrics, a leader in fingerprint verification software, on a new Fingerprint on Display (FoD) solution for the mobile industry. While increasing resolution unquestionably remains a major trend within the

Isorg, a pioneer in Organic PhotoDetectors (OPDs) and large area image sensors, has announced the FBI certification of Bio1Print30, a large-area optical fingerprint sensor for applications where enhanced mobile security and nomad ID authentication are key. The Bio1Print30, a FAP30 (Fingerprint Acquisition Profile) device, whose core technology is compatible with

NorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a biotech company developing novel and innovative strategies for the treatment of non-alcoholic steatohepatitis (NASH) and other metabolic diseases, has provided an update on its clinical pipeline of structurally engineered fatty acids (‘SEFAs’), a new class of fatty acids drugs, for the treatment

Novadip Biosciences SA (“Novadip” or “the Company”), a clinical-stage biopharmaceutical company developing a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment, has announced positive data from its Phase 1/2 clinical trial evaluating the safety and clinical activity of its